Abstracts tagged "dermatomyositis"

Abstract Number: 1383 • ACR Convergence 2022
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Rebecca Olveda, Jessica Neely and Susan Kim, UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
Abstract Number: 1879 • ACR Convergence 2022
Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies
jiram torres-Ruiz¹, Abdiel Absalón-Aguilar², Juan Alberto Reyes-Islas², Alfredo Pérez-Fragoso², Nancy R Mejía-Domínguez³, guillermo Juárez-Vega⁴, Alejandro Alfaro-Goldaracena⁵, Beatriz Alcalá-Carmona², Guillermo Juárez-Vega³, Fabiola Cassiano-Quezada² and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, ⁵Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
Abstract Number: 0043 • ACR Convergence 2022
Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
Jessica Turnier¹, Celine Berthier², Madison McClune², Sarah Vandenbergen², Johann Gudjonsson², Alex Tsoi² and J. Michelle Kahlenberg², ¹University of Michigan, Saline, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) frequently persists even in the absence of active muscle disease. Tape stripping is a non-invasive skin sampling method…
Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Yoshiyuki Abe¹, Masahiro Kogami², Makio Kusaoi², Kurisu Tada³, Ken yamaji⁴ and Naoto Tamura³, ¹Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo University, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
Abstract Number: 0714 • ACR Convergence 2021
Diagnostic Accuracy of Electromyogram for Myositis
Lois bolko¹, Sarah Leonard Louis², Jean hugues Salmon¹, Olivier Benveniste³, Yves Allenbach³ and Thierry Maisonobe⁴, ¹Rheumatology, CHU maison blanche, Reims, Reims, France, ²Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
Background/Purpose: The skeletal muscle biopsy is the gold standard for idiopathic inflammatory myopathies (IIM) diagnosis. Myositis specific antibodies are diagnostic biomarkers for IIM but are…
Abstract Number: 0687 • ACR Convergence 2021
Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
Christopher Mecoli¹, Eleni Tiniakou², William Kelly², Jemima Albayda², Julie Paik², Brittany Adler², Andrew Mammen³, Cheng Ting Lin¹, Sonye Danoff⁴, Livia Casciola-Rosen⁵ and Lisa Christopher-Stine², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴Johns Hopkins Medicine, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD
Background/Purpose: We describe a single-center North American adult cohort of MDA5-positive DM, with emphasis on the subgroup of patients that experience drug-free long-term remission. Methods:…
Abstract Number: 0719 • ACR Convergence 2021
Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies
Gözde Kübra Yardımcı¹, Arzu Taghiyeva², Enes Erul², Bayram Farisogulları³, Levent Kilic¹ and Sule Apraş Bilgen¹, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²HACETTEPE UNIVERSITY, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
Abstract Number: 0688 • ACR Convergence 2021
Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Takeru Igusa², Mengkun Chen³, XingYao Wang², Jemima Albayda², Julie Paik², Eleni Tiniakou², Brittany Adler², Carrie Richardson⁴, William Kelly², Sonye Danoff⁵, Andrew Mammen⁶, Elizabeth Platz³, Antony Rosen², Lisa Christopher-Stine², Livia Casciola-Rosen⁷ and Ami Shah⁸, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins School of Public Health, Baltimore, MD, ⁴Rush University Medical Center, Chicago, IL, ⁵Johns Hopkins Medicine, Baltimore, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 0689 • ACR Convergence 2021
Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort
Vanessa Kronzer¹, Bradly Kimbrough², Cynthia Crowson³, John Davis¹, Marie Holmqvist⁴ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan & Peter 1975 criteria, and most were not population-based.…
Abstract Number: 0756 • ACR Convergence 2021
Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis
R Naveen¹, Darpan R Thakare², Vikas Agarwal², Rohit Aggarwal³ and Latika Gupta¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
Abstract Number: 0695 • ACR Convergence 2021
Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis¹, Elena Schiopu⁸, Jiri Vencovsky⁹, Irene Beckmann¹⁰, Elisabeth Clodi¹⁰, Todd Levine¹¹ and and the ProDERM Investigators¹², ¹University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ³Friedrich-Baur-Institut/Medical University Munich, München, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸University of Michigan, Ann Arbor, MI, ⁹Institute of Rheumatology, Prague, Czech Republic, ¹⁰Octapharma PPG, Vienna, Austria, ¹¹Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹²Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with characteristic skin rash and muscle weakness. Intravenous immunoglobulin (IVIg) has long been used as adjuvant…
Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Jessica Neely¹, Kaveh Ardalan², Adam Huber³ and Susan Kim⁴, ¹University of California San Francisco, San Francisco, CA, ²Duke University Medical Center, Durham, NC, ³Dalhousie University, Halifax, NS, Canada, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
Abstract Number: 0696 • ACR Convergence 2021
Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study
Lara Dani¹, Sandra Selickaja², Angeles Shunashy Galindo-Feria³, John Svensson⁴, Paulius Venalis⁵, Dag Leonard⁶, Malin Hemberg⁷, Balsam Hanna⁸, Ingrid E Lundberg⁹ and Marie Holmqvist⁴, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²State Research Institute for Innovative Medicine and Vilnius university hospital Santaros Klinikos, Vilnius, Lithuania, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Rheumatology, Uppsala University, Uppsala, Sweden, ⁷Rheumatology Unit, Falu Lasarett, Falun, Sweden, ⁸Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁹Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: To longitudinally follow the levels of anti- transcriptional intermediary factor (TIF)1-gamma autoantibodies in patients with dermatomyositis with and without cancer.Methods: We identified sera from…
Abstract Number: 0773 • ACR Convergence 2021
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Ly-Lan Bergeron², Samantha Dill², MIchelle O'Brien², Xiaobai Li³, Jomy George³, April Brundidge², Michelle Millwood², Lisa Rider⁴ and Robert Colbert⁵, ¹Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, ²Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH/NIAMS, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].